Clinical Trial Update: Testing a New Imaging Agent to Identify Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a new imaging agent to identify HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression | Phase 1 | Status: ACTIVE_NOT_RECRUITING